Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hospitals, Insurers Enjoy Growing Influence As VCs

This article was originally published in Start Up

Executive Summary

Over a decade ago, hospital companies began establishing venture capital funds to ride shotgun with institutional VCs, hoping to get a glimpse of health care’s future. Today, under health care reform, VC groups sponsored by providers and payors increasingly find themselves in the driver’s seat, looking for the start-ups that might have solutions to the industry’s biggest problem – cost.

You may also be interested in...



Financings Of The Fortnight Checks The Corporate Venture Numbers

Corporate venture investment is seen as increasingly important in life sciences finance. Plus news on recent financings by Retrophin, Sophiris Bio, Regado Biosciences and Tigercat Pharma.

Device Start-Ups Reap More Corporate Venture

Corporate VCs are increasingly becoming a stable supplier of capital to medical device companies. Corporate investors have been participating in a growing percentage of deals being done, according to Elsevier’s Strategic Transactions, and remain focused on later-stage rounds.

VC Collapse Still Hasn’t Hit Bottom; Firms Seek Safety Of Late-Stage Deals

Limited partners require results in today’s difficult climate. Firms with a sound strategy to take advantage of this current climate can have success. Longitude Capital’s partners say the firm’s late-stage focus helped it secure $385 million for its second fund. Split Rock Partners, meanwhile, remains an active investor in early-stage companies in technology and medical devices, investing from a $300 million fund raised in 2009. However, the firm has adjusted its strategy somewhat since raising that fund. Split Rock now is making direct secondary investments as well. The firm is focusing principally on its own portfolio for opportunities, buying out co-investors or executives who may need liquidity.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT037868

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel